In Brief: J&J Snags NeoStrata; FDA Sets ICCR Prep; IRI Names Pacesetters
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson says its acquisition of NeoStrata will complement its existing skin-care portfolio. Meanwhile, FDA seeks public input at a meeting in advance of the upcoming International Cooperation on Cosmetics Regulation. More news in brief.
You may also be interested in...
J&J Launches Neutrogena Bright Boost, Children's Tylenol Dissolve Packs
Neutrogena Bright Boost line launches with technology borrowed from J&J's recently acquired NeoStrata high-end skin care line, worldwide consumer health chief Thibaut Mongon says. J&J also launches Children’s Tylenol Dissolve Packs.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.